BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 32492158)

  • 1. New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT.
    Elfeky R; Lucchini G; Lum SH; Ottaviano G; Builes N; Nademi Z; Battersby A; Flood T; Owens S; Cant AJ; Young H; Greener S; Walsh P; Kavanagh D; Annavarapu S; Rao K; Amrolia P; Chiesa R; Worth A; Booth C; Skinner R; Doncheva B; Standing J; Gennery AR; Qasim W; Slatter M; Veys P
    Blood Adv; 2020 Jun; 4(11):2418-2429. PubMed ID: 32492158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease.
    Kraft S; Bollinger N; Bodenmann B; Heim D; Bucher C; Lengerke C; Kleber M; Tsakiris DA; Passweg J; Tzankov A; Medinger M
    Bone Marrow Transplant; 2019 Apr; 54(4):540-548. PubMed ID: 30108323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and Role of Recipient-Specific Antibodies in Allogeneic Hematopoietic Cell Transplantation from Mismatched Related Donors.
    Sadowska-Klasa A; Dukat-Mazurek A; Zielińska H; Dębska-Zielkowska J; Piekarska A; Moszkowska G; Mensah-Glanowska P; Zaucha JM
    Transplant Cell Ther; 2024 Jan; 30(1):99.e1-99.e10. PubMed ID: 37875214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.
    Labrador J; López-Corral L; López-Godino O; Vázquez L; Cabrero-Calvo M; Pérez-López R; Díez-Campelo M; Sánchez-Guijo F; Pérez-López E; Guerrero C; Alberca I; Del Cañizo MC; Pérez-Simón JA; González-Porras JR; Caballero D
    Bone Marrow Transplant; 2014 May; 49(5):684-90. PubMed ID: 24566710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Increase in Complement Terminal Pathway Activation Marker sC5b-9 Is Predictive for the Development of Thrombotic Microangiopathy after Stem Cell Transplantation.
    Horváth O; Kállay K; Csuka D; Mező B; Sinkovits G; Kassa C; Stréhn A; Csordás K; Sinkó J; Prohászka Z; Kriván G
    Biol Blood Marrow Transplant; 2018 May; 24(5):989-996. PubMed ID: 29339271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis.
    Shayani S; Palmer J; Stiller T; Liu X; Thomas SH; Khuu T; Parker PM; Khaled SK; Forman SJ; Nakamura R
    Biol Blood Marrow Transplant; 2013 Feb; 19(2):298-304. PubMed ID: 23078784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The risk factors and prognosis of transplant-associated thrombotic microangiopathy following acute graft-versus-host disease].
    Mo XD; Xu LP; Liu DH; Zhang XH; Chen H; Chen YH; Han W; Wang Y; Wang FR; Wang JZ; Liu KY; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2013 Feb; 52(2):156-60. PubMed ID: 23967613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation.
    Gavriilaki E; Sakellari I; Batsis I; Mallouri D; Bousiou Z; Vardi A; Yannaki E; Constantinou V; Tsompanakou A; Vadikoliou C; Kaloyannidis P; Bamihas G; Anagnostopoulos A
    Clin Transplant; 2018 Sep; 32(9):e13371. PubMed ID: 30080283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Body Mass Index Augments Endothelial Injury and Clinical Outcomes after Hematopoietic Stem Cell Transplantation.
    Koo J; Ziady AG; Reynaud D; Abdullah S; Luebbering N; Kahn S; Langenberg L; Strecker L; Lake K; Dandoy CE; Lane A; Myers KC; Sabulski A; Good S; Nalapareddy K; Solomon M; Siefert ME; Skala E; Jodele S; Davies SM
    Transplant Cell Ther; 2023 Nov; 29(11):704.e1-704.e8. PubMed ID: 37625594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombotic microangiopathy with concomitant GI aGVHD after allogeneic hematopoietic stem cell transplantation: Risk factors and outcome.
    Zhang XH; Liu X; Wang QM; He Y; Zhu XL; Zhang JM; Han W; Chen H; Chen YH; Wang FR; Wang JZ; Zhang YY; Mo XD; Chen Y; Wang Y; Fu HX; Chang YJ; Xu LP; Liu KY; Huang XJ
    Eur J Haematol; 2018 Feb; 100(2):171-181. PubMed ID: 29114931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critical role of the Gas6-Mer axis in endothelial dysfunction contributing to TA-TMA associated with GVHD.
    Furukawa M; Wang X; Ohkawara H; Fukatsu M; Alkebsi L; Takahashi H; Harada-Shirado K; Shichishima-Nakamura A; Kimura S; Ogawa K; Ikezoe T
    Blood Adv; 2019 Jul; 3(14):2128-2143. PubMed ID: 31300420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics of pediatric allogeneic hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA): a retrospective single-center analysis.
    Luo L; Xiong H; Chen Z; Yang L; Sun M; Lu W; Tao F; Wang Z; Li J; Li Z; Tang S
    Clin Transl Oncol; 2023 Aug; 25(8):2451-2461. PubMed ID: 36973479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurologic Complications of the Central Nervous System after Allogeneic Stem Cell Transplantation: The Role of Transplantation-Associated Thrombotic Microangiopathy as a Potential Underreported Cause.
    Sala E; Neagoie AM; Lewerenz J; Saadati M; Benner A; Gantner A; Wais V; Döhner H; Bunjes D
    Transplant Cell Ther; 2024 Jun; 30(6):586.e1-586.e11. PubMed ID: 38508452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrapatient variability in concentration/dose ratio of tacrolimus predicts transplant-associated thrombotic microangiopathy.
    Sagou K; Fukushima N; Ukai S; Goto M; Ozeki K; Kohno A
    Int J Hematol; 2021 Jan; 113(1):63-72. PubMed ID: 32876853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for transplant-associated thrombotic microangiopathy (TA-TMA): a systematic review and meta-analysis.
    Guo M; Qi J; Hou Q; Li X; Han Y
    Expert Rev Hematol; 2023 Mar; 16(3):191-203. PubMed ID: 36588482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute graft-versus-host disease increase risk and accuracy in prediction model of transplantation-associated thrombotic microangiopathy in patients with myelodysplastic syndrome.
    Zhang Z; Wang H; Qi J; Tang Y; Cai C; Zhou M; Pan T; Wu D; Han Y
    Ann Hematol; 2022 Jun; 101(6):1295-1309. PubMed ID: 35357522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis.
    Higham CS; Collins G; Shimano KA; Melton A; Kharbanda S; Winestone LE; Huang JN; Dara J; Long-Boyle JR; Dvorak CC
    Blood Adv; 2021 Apr; 5(8):2106-2114. PubMed ID: 33877298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort.
    Schoettler M; Lehmann LE; Margossian S; Lee M; Kean LS; Kao PC; Ma C; Duncan CN
    Blood Adv; 2020 Jun; 4(11):2536-2547. PubMed ID: 32516415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late transplant-associated thrombotic microangiopathy verified in bone marrow biopsy specimens is associated with chronic GVHD and viral infections.
    Hill W; Sotlar K; Hautmann A; Kolb HJ; Ullmann J; Hausmann A; Schmidt M; Tischer J; Pham TT; Rank A; Hoechstetter MA
    Eur J Haematol; 2024 May; 112(5):819-831. PubMed ID: 38243840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk and prognostic factors of transplantation-associated thrombotic microangiopathy in allogeneic haematopoietic stem cell transplantation: a nested case control study.
    Ye Y; Zheng W; Wang J; Hu Y; Luo Y; Tan Y; Shi J; Zhang M; Huang H
    Hematol Oncol; 2017 Dec; 35(4):821-827. PubMed ID: 27245857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.